This trial is evaluating whether PF-06946860 will improve 4 secondary outcomes in patients with Anorexia. Measurement will happen over the course of Week 6.
This trial requires 18 total participants across 2 different treatment groups
This trial involves 2 different treatments. PF-06946860 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Anorexia is usually associated with severe symptoms. It is hard to be diagnosed because a patient may show none of these symptoms. For example, [low body weight and decreased appetite would be some symptoms indicative of anorexia] (http://en.brit-tv.com/video/20774587/video/20793831/anorexia-symptoms-symptoms). And finally, anorexia may be caused by a deficiency of proteins and/or micronutrients. Therefore it is important to ensure a good diet for [a patient with anorexia] (http://en.brit-tv.
This condition, which seems to run in families, occurs when a small segment of the ventromedial thalamic nucleus becomes overactive. Such a change causes abnormal activation of the hypothalamus and the insula (gastric control center)—components of the central nervous system which play significant roles in the regulation of appetite. This segment is also found on the dorsal projections of the ventral nucleus of the thalamus, and may be a source of excitatory input to thalamocortical and hypothalamo-hypothalamic circuits.
Medications like protease inhibitors can be used to treat anorexia. A trial of anorexia is usually required to determine the effectiveness of these medications. Also, anorexia can be treated with a gradual reduction in calories and by increasing exercise. Physical therapy, as mentioned above, is considered as an effective treatment.\n
Anorexia can be summarized as the concept of undernutrition and eating disorder. Being underweight can have adverse physiological effects such as a low birth weight, short stature, poor immune function, weakened cardiovascular system, and an increased risk of infection. Eating disorder is divided into six groups, the main categories being bulimia and anorexia nervosa.
Although treatment can improve the physical function and the general health-related quality of life of patients with advanced cancer with significant anorexia, a certain level of baseline severity and the lack of social support at the beginning of the treatment are risk factors for a poor quality of life and should be taken into account when making a decision.
About 1/300 to 1/500 women between 1905 and 1999 in the US were affected by an anorexia (AN). This prevalence is similar to rates of AN in other developed countries, where about 1/200 to 1/1500 women are affected by an AN in every year.
PF-06946860 has an inhibitory effect on TNFα and IL-1β produced from immune cells. This effect is dose dependent; higher doses are more efficacious. The activity of PF-06946860 is long lasting. Although it was not possible to determine the duration of its effects in human clinical trials, the long-lasting effects demonstrated in rodents suggest that it is efficacious.
The difference in QoL was statistically significant. The drug administration was well tolerated, with a low percentage of adverse events. The dose-proportional relationship was determined with the two highest doses.
We could not find sufficient data in the literature for a meta-analysis to assess the effect of PF-06946860 monotherapy. No convincing results suggest that PF-06946860 is a rational add-on therapy for children with AN.
Patients with severe anorexia might need to remain in the intensive care unit to improve their respiratory status and overall survival; however, there are no conclusive data on the need for mechanical ventilation in patients with anorexia.
Although research and treatment of anorexia is progressing, the search still for an 'official' treatment of anorexia remains open. There is still a need for both more precise, and comprehensive, research studies to be conducted, aiming to give patients and their doctors proof that research and treatment are producing tangible results.\n
The most important causes of anorexia as determined in this study were low body weight and psychological factors (e.g., fear of gaining weight). In addition, family and emotional problems, such as stress, worry, or anxiety, and interpersonal issues may also influence anorexia.